Ascletis Pharma Inc (1672.HK), a commercial-stage biotechnology company that focuses on addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announced yesterday that it has named Dr Lindi Tan as its new chief financial officer.

Dr Tan is a healthcare professional with experience in the biotech sector. Prior to joining Ascletis, she held roles at SeaTown Holdings International and Temasek International. She was the global healthcare analyst at SeaTown Holdings International and was responsible for driving multi-asset investments. At Temasek International, she held an investment role in the Life Sciences team and was the staff officer to the chief investment officers/heads of investments.

Jinzi J Wu, PhD, founder, chairman and CEO of Ascletis, said, 'We are very pleased to welcome Lindi to the management team. She brings to Ascletis more than 15 years of investment, finance, research and management experience in the global healthcare sector and has a proven track record of healthcare investing and partnering. Her extensive experience, leadership, and familiarity with our business makes her an ideal choice to help lead Ascletis as we move on to the next phase of our transformation.'